Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

H

Humacyte, Inc.

Other

0

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

0

Indications↗

Distinct diseases across all programs

12

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Approved for marketing

Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular System Injuries

Temporarily not available

Individual Patient Expanded Access for Acellular Tissue Engineered Vessel (ATEV) for Vascular Disease and Dialysis Access

Earlier

Jun 27, 2026TrialA Phase 3 Randomized Study to Compare the Efficacy and Safety of the Humacyte Acellular Tissue Engineered Vessel (ATEV) With That of an Autogenous Arteriovenous Fistula (AVF) in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

May 1, 2023TrialAn Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma

Nov 12, 2019TrialSafety and Efficacy Assessment of HAV in Patients Needing Vascular Access for Dialysis

Sep 1, 2018TrialHumacyte Human Acellular Vessel (HAV) in Patients With Vascular Trauma

Sep 29, 2017TrialComparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

Dec 20, 2016TrialHumacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)